Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Conditions: B-Cell Non-Hodgkin Lymphoma-Recurrent; B-Cell Non-Hodgkin Lymphoma-Refractory Interventions: Biological: LUCAR-G39D cells product Sponsors: Tianjin Medical University Cancer Institute and Hospital; Nanjing Legend Biotech Co. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials